SCYNEXIS Welcomes Christine Coyne as Chief Commercial Officer
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

SCYNEXIS Welcomes Christine Coyne as Chief Commercial Officer

Pharma Tech Outlook | Thursday, June 10, 2021

Marco Taglietti M.D, CEO, SCYNEXIS

SCYNEXIS recently confirmed the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021.

FREMONT, CA: SCYNEXIS, Inc., a biotechnology firm pioneering advanced medicines to cure and prevent complicated and drug-resistant infections, recently confirmed the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play an essential role in the awaited release and commercialization of Brexafemme, the estimated trade name for ibrexafungerp, an oral antifungal product candidate for treating vulvovaginal candidiasis (VVC), commonly known as a vaginal yeast infection. The U.S. Food and Drug Administration (FDA) is reviewing the New Drug Application (NDA) for Brexafemme, which has a Prescription Drug User Fee Act (PDUFA) action date of June 1, 2021.

"We are thrilled to welcome Christine to the SCYNEXIS management team," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "Throughout her career, she has consistently demonstrated a strong track record in successfully launching new products and I believe her proficiency in building and leading performance-driven teams will be a significant asset for our Company. Christines extensive commercial expertise in the infectious disease space, working across both hospital and community settings, will be equally essential as we launch in our first indication and seek to broaden the ibrexafungerp label to encompass severe and life-threatening infections treated in hospitals."

Ms. Coyne added, "I am excited to join SCYNEXIS because I believe in the potential of ibrexafungerp to address a broad range of fungal infections and its value to physicians and patients who are seeking alternatives to standard of care agents, and particularly to generic fluconazole for women with vaginal yeast infections. The focused SCYNEXIS team has already accomplished a lot in bringing ibrexafungerp to where it is today. I look forward to working with these talented individuals to deliver what could be the first novel antifungal class in over 20 years and the first and only non-azole treatment for vaginal yeast infections."

Ms. Coyne brings 30 years of experience in product launch and commercialization across multiple therapeutic areas to SCYNEXIS. Ms. Coyne previously served as Senior Vice President, Commercial at Paratek Pharmaceuticals, where she helped launch the company's first product and adapting tactics to ensure success, even in the face of external challenges like the COVID-19 pandemic. Christine previously guided marketing and sales teams at biotech and large pharma firms, including Wyeth-Ayerst Global Pharmaceuticals (currently part of Pfizer), Endo, and Auxilium Pharmaceuticals (now part of Endo). Ms. Coyne earlier worked as the Vice President of Marketing, Sales, and Operations for specialty pharmaceutical companies in the United States and around the world, where she was in charge of several approved products. Ms. Coyne received her M.B.A. from Eastern University.

Weekly Brief

Read Also